Cargando…
Correction to: Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study
| Autores principales: | , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6416882/ https://www.ncbi.nlm.nih.gov/pubmed/30871617 http://dx.doi.org/10.1186/s40425-019-0559-3 |
| _version_ | 1783403449931530240 |
|---|---|
| author | Amin, Asim Plimack, Elizabeth R. Ernstoff, Marc S. Lewis, Lionel D. Bauer, Todd M. McDermott, David F. Carducci, Michael Kollmannsberger, Christian Rini, Brian I. Heng, Daniel Y. C. Knox, Jennifer Voss, Martin H. Spratlin, Jennifer Berghorn, Elmer Yang, Lingfeng Hammers, Hans J. |
| author_facet | Amin, Asim Plimack, Elizabeth R. Ernstoff, Marc S. Lewis, Lionel D. Bauer, Todd M. McDermott, David F. Carducci, Michael Kollmannsberger, Christian Rini, Brian I. Heng, Daniel Y. C. Knox, Jennifer Voss, Martin H. Spratlin, Jennifer Berghorn, Elmer Yang, Lingfeng Hammers, Hans J. |
| author_sort | Amin, Asim |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-6416882 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2019 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-64168822019-03-25 Correction to: Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study Amin, Asim Plimack, Elizabeth R. Ernstoff, Marc S. Lewis, Lionel D. Bauer, Todd M. McDermott, David F. Carducci, Michael Kollmannsberger, Christian Rini, Brian I. Heng, Daniel Y. C. Knox, Jennifer Voss, Martin H. Spratlin, Jennifer Berghorn, Elmer Yang, Lingfeng Hammers, Hans J. J Immunother Cancer Correction BioMed Central 2019-03-14 /pmc/articles/PMC6416882/ /pubmed/30871617 http://dx.doi.org/10.1186/s40425-019-0559-3 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| spellingShingle | Correction Amin, Asim Plimack, Elizabeth R. Ernstoff, Marc S. Lewis, Lionel D. Bauer, Todd M. McDermott, David F. Carducci, Michael Kollmannsberger, Christian Rini, Brian I. Heng, Daniel Y. C. Knox, Jennifer Voss, Martin H. Spratlin, Jennifer Berghorn, Elmer Yang, Lingfeng Hammers, Hans J. Correction to: Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study |
| title | Correction to: Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study |
| title_full | Correction to: Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study |
| title_fullStr | Correction to: Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study |
| title_full_unstemmed | Correction to: Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study |
| title_short | Correction to: Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study |
| title_sort | correction to: safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the checkmate 016 study |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6416882/ https://www.ncbi.nlm.nih.gov/pubmed/30871617 http://dx.doi.org/10.1186/s40425-019-0559-3 |
| work_keys_str_mv | AT aminasim correctiontosafetyandefficacyofnivolumabincombinationwithsunitiniborpazopanibinadvancedormetastaticrenalcellcarcinomathecheckmate016study AT plimackelizabethr correctiontosafetyandefficacyofnivolumabincombinationwithsunitiniborpazopanibinadvancedormetastaticrenalcellcarcinomathecheckmate016study AT ernstoffmarcs correctiontosafetyandefficacyofnivolumabincombinationwithsunitiniborpazopanibinadvancedormetastaticrenalcellcarcinomathecheckmate016study AT lewislioneld correctiontosafetyandefficacyofnivolumabincombinationwithsunitiniborpazopanibinadvancedormetastaticrenalcellcarcinomathecheckmate016study AT bauertoddm correctiontosafetyandefficacyofnivolumabincombinationwithsunitiniborpazopanibinadvancedormetastaticrenalcellcarcinomathecheckmate016study AT mcdermottdavidf correctiontosafetyandefficacyofnivolumabincombinationwithsunitiniborpazopanibinadvancedormetastaticrenalcellcarcinomathecheckmate016study AT carduccimichael correctiontosafetyandefficacyofnivolumabincombinationwithsunitiniborpazopanibinadvancedormetastaticrenalcellcarcinomathecheckmate016study AT kollmannsbergerchristian correctiontosafetyandefficacyofnivolumabincombinationwithsunitiniborpazopanibinadvancedormetastaticrenalcellcarcinomathecheckmate016study AT rinibriani correctiontosafetyandefficacyofnivolumabincombinationwithsunitiniborpazopanibinadvancedormetastaticrenalcellcarcinomathecheckmate016study AT hengdanielyc correctiontosafetyandefficacyofnivolumabincombinationwithsunitiniborpazopanibinadvancedormetastaticrenalcellcarcinomathecheckmate016study AT knoxjennifer correctiontosafetyandefficacyofnivolumabincombinationwithsunitiniborpazopanibinadvancedormetastaticrenalcellcarcinomathecheckmate016study AT vossmartinh correctiontosafetyandefficacyofnivolumabincombinationwithsunitiniborpazopanibinadvancedormetastaticrenalcellcarcinomathecheckmate016study AT spratlinjennifer correctiontosafetyandefficacyofnivolumabincombinationwithsunitiniborpazopanibinadvancedormetastaticrenalcellcarcinomathecheckmate016study AT berghornelmer correctiontosafetyandefficacyofnivolumabincombinationwithsunitiniborpazopanibinadvancedormetastaticrenalcellcarcinomathecheckmate016study AT yanglingfeng correctiontosafetyandefficacyofnivolumabincombinationwithsunitiniborpazopanibinadvancedormetastaticrenalcellcarcinomathecheckmate016study AT hammershansj correctiontosafetyandefficacyofnivolumabincombinationwithsunitiniborpazopanibinadvancedormetastaticrenalcellcarcinomathecheckmate016study |